- Home
- MRSN
as 11-14-2025 3:46pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 47.1M | IPO Year: | 2017 |
| Target Price: | $30.38 | AVG Volume (30 days): | 211.4K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.21 - $70.73 | Next Earning Date: | 11-14-2025 |
| Revenue: | $33,180,000 | Revenue Growth: | -4.76% |
| Revenue Growth (this year): | -36.29% | Revenue Growth (next year): | -22.12% |
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bala Mohan | MRSN | SVP, Chief Development Officer | Oct 27 '25 | Sell | $9.90 | 77 | $762.30 | 2,922 | |
| Huber Martin H. Jr. | MRSN | President, CEO | Sep 12 '25 | Sell | $7.31 | 2,012 | $14,707.72 | 9,572 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
How the Acquisition Is Reshaping Mersana Therapeutics’ Story and Analyst Outlook
Zacks
2 days ago
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
MT Newswires
2 days ago
William Blair Downgrades Mersana Therapeutics to Market Perform From Outperform
GlobeNewswire
2 days ago
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
Investor's Business Daily
3 days ago
Mersana Therapeutics Catapults 200% On Day One Bio's Surprise Buyout
MT Newswires
3 days ago
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT Newswires
3 days ago
Sector Update: Health Care
MT Newswires
3 days ago
Top Midday Gainers
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.